Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer - Report - MDSpire
Advertisement
Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer
Clinical Report: Hematological Indicators for Pathological Outcomes in LAGC
Overview
This study identifies pre-treatment neutrophil count and post-treatment albumin as independent predictors of major pathologic response (MPR) in locally advanced gastric cancer (LAGC) patients undergoing neoadjuvant immunochemotherapy (NICT). Additionally, it highlights the potential benefit of extended therapy cycles for patients with low pre-treatment neutrophil levels.
Background
Gastric cancer is a leading cause of cancer-related mortality worldwide, and neoadjuvant immunochemotherapy (NICT) has emerged as a promising treatment strategy for locally advanced gastric cancer (LAGC). Understanding the predictive value of hematological parameters can help identify patients who are more likely to benefit from NICT, thereby optimizing treatment strategies and improving outcomes.
Data Highlights
Parameter
Adjusted Odds Ratio (OR)
95% Confidence Interval (CI)
P-value
Pre-treatment Neutrophil Count
0.83
0.70–0.99
0.033
Post-treatment Albumin
0.92
0.85–1.00
0.042
Post-treatment Platelet Count
1.01
1.00–1.01
0.014
Key Findings
Pre-treatment neutrophil count is an independent protective factor for MPR in LAGC patients receiving NICT.
Post-treatment albumin levels are also predictive of MPR.
Post-treatment platelet count serves as an independent risk factor for MPR.
Patients with pre-treatment neutrophils <3.39×109/L benefit significantly from receiving 4 cycles of NICT.
Extended neoadjuvant therapy correlates with higher pathologic complete response rates in specific patient subgroups.
Clinical Implications
Clinicians should consider pre-treatment neutrophil counts and post-treatment albumin levels when assessing the likelihood of pathologic response to NICT in LAGC patients. Additionally, extending the number of treatment cycles for patients with low pre-treatment neutrophil counts may enhance therapeutic outcomes.
Conclusion
The findings underscore the importance of hematological parameters in predicting treatment responses in LAGC, suggesting that tailored neoadjuvant strategies could improve patient outcomes.
